Information Provided By: 
Fly News Breaks for March 3, 2020
FATE
Mar 3, 2020 | 05:07 EDT
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Fate Therapeutics to $57 from $28 and reiterates an Overweight rating on the shares. The analyst rolled forward the company's discount period to year-end 2020 and added pipeline value. The company ended 2019 with cash of $261M and is now focusing FT500 in non-small-cell lung carcinoma, Tenthoff tells investors in a research note.
News For FATE From the Last 2 Days
FATE
Apr 18, 2024 | 17:52 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSMetropolitan... To see the rest of the story go to thefly.com. See Story Here
